An attenuated monocyte-tropic clone of SIV (SIV/17E-C1) has properties which are unique to a live attenuated SIV vaccine. Infection with SIV/17E-C1 induces an early vigorous type-specific neutralizing antibody response which broadens during the first 7 months postinfection to include activity against SIV/DeltaB670, a heterologous primary isolate. The induction of protective immune responses coincides with the switch from type-specific to group-specific neutralizing antibody, and, at least in part, appears mediated by antibody since sera from protected monkeys passively protected 2 of 4 recipients. A nef-deleted variant of this monocyte-tropic clone, but not the lymphocyte-tropic parent SIVmac239deltanef, also induced detectable class I restricted CTL during the first 6 months postinfection. These unique properties are likely due to a unique gp120 conformation imposed by sequences which enable it to replicate in macrophages, and/or selective presentation to the immune system by the infected macrophage. We propose to further characterize the protective responses induced by SIV/17E-C1 infection, and to utilize this information to design a subunit vaccine that can induce the protective responses observed with the attenuated virus. The protection observed by intravenous challenge with cell-free virus of SIV/e-C1- infected monkeys will be extended to protection against infected cells, delivered both intravenously and at the intestinal mucosal surface. The role of antibody in passive protection will be confirmed by passive transfer of purified immunoglobulin. Antibodies binding to native versus denatured gp120 will be affinity purified, characterized in vitro and similarly analyzed to define the specificity of protective responses. Passive transfer studies will also be performed with monoclonal antibodies derived from SIV/17E-C1-infected monkeys to identify the specific epitope(s) required for protection. The contribution of cellular immunity will be determined by determining the kinetics of class I restricted CTL induction in infected monkeys, and correlating these responses to protection. The efficacy of a purified recombinant gp120 vaccine comprised of SIV/17E-C1 sequences will be evaluated to determine whether these sequences per se uniquely induce protective immunity. The ability of DNA vaccines comprised of SIV/17E sequences, alone or in combination with cytokine expression vectors, to elicit protective responses will be assessed using both direct injection of DNA and the particle delivery system developed by Agracetus. The optimal HIV vaccine strategy is one which is efficacious in both SIV (disease) and HIV (infection) model systems. Thus, the ability of SIV/HIV recombinant viruses to serve as live attenuated vaccines will be determined to extend the observations gained from SIV to HIV glycoproteins. A model for assessing effective SIV subunit vaccines, as well as heterologous (inter- clade) protection, will be established using SHIV constructs.

Project Start
2000-04-01
Project End
2001-03-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
12
Fiscal Year
2000
Total Cost
$351,855
Indirect Cost
Name
University of Pittsburgh
Department
Type
DUNS #
053785812
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Steckbeck, J D; Grieser, H J; Sturgeon, T et al. (2006) Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol 35:248-60
Sarkar, Surojit; Kalia, Vandana; Murphey-Corb, Michael et al. (2003) Expression of IFN-gamma induced CXCR3 agonist chemokines and compartmentalization of CXCR3+ cells in the periphery and lymph nodes of rhesus macaques during simian immunodeficiency virus infection and acquired immunodeficiency syndrome. J Med Primatol 32:247-64
Sarkar, Surojit; Kalia, Vandana; Montelaro, Ronald C (2003) Caspase-mediated apoptosis and cell death of rhesus macaque CD4+ T-cells due to cryopreservation of peripheral blood mononuclear cells can be rescued by cytokine treatment after thawing. Cryobiology 47:44-58
Sarkar, Surojit; Kalia, Vandana; Murphey-Corb, Michael et al. (2002) Detailed analysis of CD4+ Th responses to envelope and Gag proteins of simian immunodeficiency virus reveals an exclusion of broadly reactive Th epitopes from the glycosylated regions of envelope. J Immunol 168:4001-11
Sarkar, S; Kalia, V; Murphey-Corb, M et al. (2002) Characterization of CD4+ T helper cell fine specificity to the envelope glycoproteins of simian immunodeficiency virus. J Med Primatol 31:194-204
Seman, A L; Pewen, W F; Fresh, L F et al. (2000) The replicative capacity of rhesus macaque peripheral blood mononuclear cells for simian immunodeficiency virus in vitro is predictive of the rate of progression to AIDS in vivo. J Gen Virol 81:2441-9
Cole, K S; Murphey-Corb, M; Narayan, O et al. (1998) Common themes of antibody maturation to simian immunodeficiency virus, simian-human immunodeficiency virus, and human immunodeficiency virus type 1 infections. J Virol 72:7852-9